ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 22.55 TWD 0.89% Market Closed
Market Cap: 17.8B TWD
Have any thoughts about
ScinoPharm Taiwan Ltd?
Write Note

ScinoPharm Taiwan Ltd
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ScinoPharm Taiwan Ltd
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
ScinoPharm Taiwan Ltd
TWSE:1789
Retained Earnings
NT$1.3B
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
3%
Y
YungShin Global Holding Corp
TWSE:3705
Retained Earnings
NT$2.9B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
13%
Formosa Laboratories Inc
TWSE:4746
Retained Earnings
NT$2.8B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
24%
S
SCI Pharmtech Inc
TWSE:4119
Retained Earnings
NT$2B
CAGR 3-Years
22%
CAGR 5-Years
10%
CAGR 10-Years
12%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Retained Earnings
NT$11.6B
CAGR 3-Years
102%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Standard Chem & Pharm Co Ltd
TWSE:1720
Retained Earnings
NT$3.5B
CAGR 3-Years
17%
CAGR 5-Years
17%
CAGR 10-Years
16%
No Stocks Found

ScinoPharm Taiwan Ltd
Glance View

Market Cap
17.8B TWD
Industry
Pharmaceuticals

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.

Intrinsic Value
17.52 TWD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is ScinoPharm Taiwan Ltd's Retained Earnings?
Retained Earnings
1.3B TWD

Based on the financial report for Sep 30, 2024, ScinoPharm Taiwan Ltd's Retained Earnings amounts to 1.3B TWD.

What is ScinoPharm Taiwan Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
3%

Over the last year, the Retained Earnings growth was 11%. The average annual Retained Earnings growth rates for ScinoPharm Taiwan Ltd have been 4% over the past three years , 4% over the past five years , and 3% over the past ten years .

Back to Top